DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Kampmann Melissa S.

Kampmann Melissa S. decreased its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 19.2% in the 4th quarter, HoldingsChannel.com reports. The fund owned 33,335 shares of the medical device company’s stock after selling 7,905 shares during the quarter. DexCom accounts for about 2.0% of Kampmann Melissa S.’s holdings, making the stock its 27th biggest holding. Kampmann Melissa S.’s holdings in DexCom were worth $2,592,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Versant Capital Management Inc acquired a new position in shares of DexCom during the fourth quarter valued at $25,000. Private Trust Co. NA lifted its holdings in DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock worth $26,000 after purchasing an additional 245 shares during the period. Larson Financial Group LLC lifted its holdings in DexCom by 40.5% in the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock worth $37,000 after purchasing an additional 137 shares during the period. Heck Capital Advisors LLC acquired a new stake in DexCom in the fourth quarter worth about $38,000. Finally, SBI Securities Co. Ltd. acquired a new stake in DexCom in the fourth quarter worth about $49,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analyst Ratings Changes

DXCM has been the subject of several research analyst reports. Canaccord Genuity Group upped their price objective on shares of DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a report on Friday, February 14th. Redburn Atlantic raised shares of DexCom from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $85.00 to $115.00 in a report on Monday, February 3rd. Wells Fargo & Company reaffirmed an “overweight” rating on shares of DexCom in a report on Saturday, March 8th. Morgan Stanley upped their price objective on shares of DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a report on Friday, February 14th. Finally, Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $99.82.

DexCom Trading Up 3.8 %

NASDAQ DXCM opened at $73.38 on Thursday. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The stock has a market cap of $28.67 billion, a price-to-earnings ratio of 51.31, a PEG ratio of 2.30 and a beta of 1.28. The firm’s 50 day moving average price is $83.51 and its two-hundred day moving average price is $76.93.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Equities analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Activity

In other news, COO Jacob Steven Leach sold 14,076 shares of the business’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $990,668.88. Following the transaction, the chief operating officer now directly owns 313,497 shares in the company, valued at $22,063,918.86. The trade was a 4.30 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Jereme M. Sylvain sold 2,090 shares of the company’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the sale, the executive vice president now owns 83,526 shares of the company’s stock, valued at $7,259,244.66. This represents a 2.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 105,009 shares of company stock worth $8,044,178 in the last ninety days. Corporate insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.